JP2022502358A5 - - Google Patents

Info

Publication number
JP2022502358A5
JP2022502358A5 JP2021514549A JP2021514549A JP2022502358A5 JP 2022502358 A5 JP2022502358 A5 JP 2022502358A5 JP 2021514549 A JP2021514549 A JP 2021514549A JP 2021514549 A JP2021514549 A JP 2021514549A JP 2022502358 A5 JP2022502358 A5 JP 2022502358A5
Authority
JP
Japan
Prior art keywords
peptide
cancer
fragment
antibody
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021514549A
Other languages
English (en)
Japanese (ja)
Other versions
JP7476174B2 (ja
JP2022502358A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/075065 external-priority patent/WO2020058360A1/en
Publication of JP2022502358A publication Critical patent/JP2022502358A/ja
Publication of JP2022502358A5 publication Critical patent/JP2022502358A5/ja
Priority to JP2024067065A priority Critical patent/JP2024102112A/ja
Application granted granted Critical
Publication of JP7476174B2 publication Critical patent/JP7476174B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514549A 2018-09-18 2019-09-18 がんに対するａ＊０１拘束性ペプチドおよびペプチド組み合わせによる免疫療法 Active JP7476174B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024067065A JP2024102112A (ja) 2018-09-18 2024-04-17 がんに対するａ＊０１拘束性ペプチドおよびペプチド組み合わせによる免疫療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862732863P 2018-09-18 2018-09-18
DE102018122900.3 2018-09-18
US62/732,863 2018-09-18
DE102018122900 2018-09-18
PCT/EP2019/075065 WO2020058360A1 (en) 2018-09-18 2019-09-18 Immunotherapy with a*01 restricted peptides and combination of peptides against cancers and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024067065A Division JP2024102112A (ja) 2018-09-18 2024-04-17 がんに対するａ＊０１拘束性ペプチドおよびペプチド組み合わせによる免疫療法

Publications (3)

Publication Number Publication Date
JP2022502358A JP2022502358A (ja) 2022-01-11
JP2022502358A5 true JP2022502358A5 (enExample) 2023-06-16
JP7476174B2 JP7476174B2 (ja) 2024-04-30

Family

ID=68062920

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021514549A Active JP7476174B2 (ja) 2018-09-18 2019-09-18 がんに対するａ＊０１拘束性ペプチドおよびペプチド組み合わせによる免疫療法
JP2024067065A Pending JP2024102112A (ja) 2018-09-18 2024-04-17 がんに対するａ＊０１拘束性ペプチドおよびペプチド組み合わせによる免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024067065A Pending JP2024102112A (ja) 2018-09-18 2024-04-17 がんに対するａ＊０１拘束性ペプチドおよびペプチド組み合わせによる免疫療法

Country Status (19)

Country Link
US (10) US10954281B2 (enExample)
EP (1) EP3852787A1 (enExample)
JP (2) JP7476174B2 (enExample)
KR (1) KR20210063320A (enExample)
CN (1) CN113164569A (enExample)
AU (1) AU2019342860A1 (enExample)
BR (1) BR112021003511A2 (enExample)
CA (1) CA3108582A1 (enExample)
CL (3) CL2021000653A1 (enExample)
CO (1) CO2021003404A2 (enExample)
CR (1) CR20210141A (enExample)
IL (2) IL309715A (enExample)
MA (1) MA53644A (enExample)
MX (1) MX2021003089A (enExample)
PE (1) PE20211643A1 (enExample)
PH (1) PH12021550581A1 (enExample)
SG (1) SG11202101926TA (enExample)
TW (1) TW202024121A (enExample)
WO (1) WO2020058360A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018189148A1 (en) 2017-04-10 2018-10-18 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
BR112019020959A2 (pt) 2017-04-10 2020-05-05 Immatics Biotechnologies Gmbh peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer
WO2021188743A2 (en) * 2020-03-20 2021-09-23 Neo7Logix, Llc Precision-based immuno-molecular augmentation (pbima) computerized system, method and therapeutic vaccine
US12525329B2 (en) * 2020-03-20 2026-01-13 Neo7Bioscience, Inc. Precision-based immuno-molecular augmentation (PBIMA) computerized system, method, and therapeutic vaccine
CA3173666A1 (en) * 2020-04-14 2021-10-21 Claude Perreault Novel tumor-specific antigens for acute myeloid leukemia (aml) and uses thereof
CN115843747B (zh) * 2022-12-02 2024-08-20 吉林大学 一种Lama3基因点突变的小鼠模型及其构建方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
LU88258I2 (enExample) 1978-12-22 1994-02-03
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
AU7524601A (en) 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
PT1558643E (pt) 2002-11-09 2009-08-24 Immunocore Ltd Apresentação de um receptor das células t
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
SI1806358T1 (sl) 2005-09-05 2010-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2632955A1 (en) 2010-10-26 2013-09-04 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
ES2603589T3 (es) 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
BR112017022845A2 (pt) 2015-04-23 2018-07-17 Nantomics, Llc neoepítopos de câncer
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201520559D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
US11175289B2 (en) * 2016-11-16 2021-11-16 Lei Han Application of TRPM8 protein, related peptide fragment and their antibodies
SG11201911430PA (en) 2017-07-04 2020-01-30 Curevac Ag Novel nucleic acid molecules

Similar Documents

Publication Publication Date Title
JP2024041841A5 (enExample)
JP2024099580A5 (enExample)
JP2021535900A5 (enExample)
JP2022502015A5 (enExample)
JP2022502358A5 (enExample)
JP2019511214A5 (enExample)
JP2021168652A5 (enExample)
JP2019502360A5 (enExample)
JP2021514178A5 (enExample)
EP2951202B1 (en) High avidity binding molecules recognizing mage-a1
JP2020516681A5 (enExample)
JP2021528046A5 (enExample)
JP2019510465A5 (enExample)
JP2018510628A5 (enExample)
JP2020191862A5 (enExample)
JP2020198875A5 (enExample)
JP2018529320A5 (enExample)
JP2019506838A5 (enExample)
JP2019516663A5 (enExample)
JP2018536383A5 (enExample)
JP2018520653A5 (enExample)
RU2017137142A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
JP2018509135A5 (enExample)
JP2018518937A5 (enExample)
JP2018519243A5 (enExample)